# Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

> **NCT06719700** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 47 (estimated)

## Conditions studied

- Toripalimab
- Surufatinib
- Chemoradiotherapy
- Limited-stage Small Cell Lung Cancer (LS-SCLC)

## Interventions

- **DRUG:** Chemotherapy
- **DRUG:** Immunotherapy
- **DRUG:** Angio-immuno kinase inhibitor
- **RADIATION:** radiotherapy
- **RADIATION:** Prophylactic Cranial Irradiation
- **DRUG:** Consolidation Therapy with Toripalimab and Surufatinib

## Key facts

- **NCT ID:** NCT06719700
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-30
- **Primary completion:** 2028-11-29
- **Final completion:** 2028-11-29
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06719700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06719700, "Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06719700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*